Evidence map›Paper›PMID 30559212›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis.

Isabel Cordero-Herrera, Mikael Kozyra, Zhengbing Zhuge, Sarah McCann Haworth, Chiara Moretti, Maria Peleli, Mayara Caldeira-Dias, Arghavan Jahandideh, Han Huirong, Josiane de Campos Cruz and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 99 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  19. Review
  20. Plants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Isabel Cordero-HerreraDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Mikael KozyraDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Zhengbing ZhugeDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Sarah McCann HaworthDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Chiara MorettiDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Maria PeleliDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Mayara Caldeira-DiasDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Arghavan JahandidehDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Han HuirongDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Josiane de Campos CruzDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Andrei L KleschyovDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Marcelo F MontenegroDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Magnus Ingelman-SundbergDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Eddie WeitzbergDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Jon O LundbergDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden; jon.lundberg@ki.se mattias.carlstrom@ki.se.
Mattias CarlstromDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden; jon.lundberg@ki.se mattias.carlstrom@ki.se.ORCID 0000-0001-9923-8729
Karolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced age and unhealthy dietary habits contribute to the increasing incidence of obesity and type 2 diabetes. These metabolic disorders, which are often accompanied by oxidative stress and compromised nitric oxide (NO) signaling, increase the risk of adverse cardiovascular complications and development of fatty liver disease. Here, we investigated the therapeutic effects of dietary nitrate, which is found in high levels in green leafy vegetables, on liver steatosis associated with metabolic syndrome. Dietary nitrate fuels a nitrate-nitrite-NO signaling pathway, which prevented many features of metabolic syndrome and liver steatosis that developed in mice fed a high-fat diet, with or without combination with an inhibitor of NOS (l-NAME). These favorable effects of nitrate were absent in germ-free mice, demonstrating the central importance of host microbiota in bioactivation of nitrate. In a human liver cell line (HepG2) and in a validated hepatic 3D model with primary human hepatocyte spheroids, nitrite treatment reduced the degree of metabolically induced steatosis (i.e., high glucose, insulin, and free fatty acids), as well as drug-induced steatosis (i.e., amiodarone). Mechanistically, the salutary metabolic effects of nitrate and nitrite can be ascribed to nitrite-derived formation of NO species and activation of soluble guanylyl cyclase, where xanthine oxidoreductase is proposed to mediate the reduction of nitrite. Boosting this nitrate-nitrite-NO pathway results in attenuation of NADPH oxidase-derived oxidative stress and stimulation of AMP-activated protein kinase and downstream signaling pathways regulating lipogenesis, fatty acid oxidation, and glucose homeostasis. These findings may have implications for novel nutrition-based preventive and therapeutic strategies against liver steatosis associated with metabolic dysfunction.

Indexed as

AMP-Activated Protein KinasesAnimalsEnzyme ActivationFatty LiverHepatocytesHep G2 CellsHumansLiverMaleMiceMice, Inbred C57BLNADPH OxidasesNitratesNitric OxideNitritesAMP-Activated Protein KinasesNADPH OxidasesNitratesNitric OxideNitritesmicrobiotanitratenitric oxidenitritesteatosis

Identifiers

PMID30559212
PMCPMC6320503
OpenAlexW2904952754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.